|
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients Clinical research trials and The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients. The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients clinical trial. Participants frequently obtain the most expert healthcare available for their The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients  The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Merck Research Laboratories ,
Synopsis: To evaluate, in HIV-infected patients whose baseline CD4 count is 300 to 750 cells/mm3, whether an antiretroviral treatment regimen based upon clinical evaluation and CD4 counts plus HIV RNA viral load is more effective than a treatment regimen based upon clinical evaluation and CD4 counts without the use of HIV RNA viral load information. To assess relative utility of viral load testing in determining therapeutic choice by the surrogate marker of CD4 cell counts after 48 weeks of therapy. It is hypothesized that among HIV-infected patients whose baseline CD4 count is in the range of 300 to 750 cells/mm3, those patients who incorporate initial and periodic viral RNA measurements in their therapeutic decisions will have higher CD4 counts after 48 weeks than patients whose therapeutic decisions do not incorporate initial and periodic viral RNA measurements.
Details: It is hypothesized that among HIV-infected patients whose baseline CD4 count is in the range of 300 to 750 cells/mm3, those patients who incorporate initial and periodic viral RNA measurements in their therapeutic decisions will have higher CD4 counts after 48 weeks than patients whose therapeutic decisions do not incorporate initial and periodic viral RNA measurements. Approximately 540 patients are stratified on the basis of baseline CD4 counts and are randomized to one of two treatment groups: 1. viral RNA treatment group or 2. non viral RNA treatment group. Treatment modification is based upon CD4 count, viral RNA levels (group 1 only) and clinical evaluation. Patients receive one of the three antiretroviral treatments: 1. No antiretroviral therapy. 2. Double reverse transcriptase inhibitor (RTI) therapy consisting of any two therapy combinations of: didanosine (ddI), lamivudine (3TC), stavudine (d4T) or zidovudine (ZDV), based upon the treating physician's judgment. The preferred combinations are ZDV + 3TC, d4T + 3TC or ddI + d4T. 3. Triple antiretroviral therapy consisting of double antiretroviral therapy plus indinavir. Treatment decisions are based upon a standardized algorithm as follows: CD4 count 500-750 + viral RNA < 10,000: Group 1: No retroviral therapy. Group 2: No retroviral therapy. CD4 count 500-750 + viral RNA >= 10,000: Group 1: Triple therapy. Group 2: No retroviral therapy. CD4 count 300-499 + viral RNA < 10,000: Group 1: Double retroviral therapy. Group 2: Double retroviral therapy. CD4 count 300-499 + viral RNA >= 10,000: Group 1: Triple therapy. Group 2: Double retroviral therapy. CD4 count 200-299 + viral RNA < 10,000: Group 1: Maintain same retroviral therapy unless: there is a CD4 count decrease of 25-49% within 24 weeks of the count falling in the range of 300-499 in which case both retroviral therapies are changed, there is a CD4 count decrease of >= 50% within the 48 weeks of therapy from the time the CD4 count fell within the range of 300-499 in which case triple therapy is initiated, or there is an AIDS-defining illness in which case triple therapy is initiated. Group 2: Same as Group 1. CD4 count 200-299 + viral RNA >= 10,000: Group 1: Triple therapy. Group 2: Maintain same retroviral therapy unless: there is a CD4 count decrease of 25-49% within 24 weeks of the count falling in the range of 300-499 in which case both retroviral therapies are changed, there is a CD4 count decrease of >= 50% within the 48 weeks of therapy from the time the CD4 count fell within the range of 300-499 in which case triple therapy is initiated, or there is an AIDS-defining illness in which case triple therapy is initiated. CD4 count < 200: Group 1: Triple therapy. Group 2: Triple therapy.
Eligibility:
Study Type: Interventional, Treatment, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: CD4 count >= 300 and <= 750 cells/mm3. Exclusion Criteria Prior Medication: Excluded: Prior protease inhibitor therapy.
Total Enrollment: 540
Location and Contact Information:
Kaiser Foundation Hospital
San Francisco, California, 94118
United States
Additional Information:
Study ID Numbers: 246F; MK-0639,056-00
Study Start Date:
Record last reviewed: June 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002376
Other Hiv Infections Studies:
1. A Study of Megestrol Acetate in HIV-Infected Children
2. Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients
3. Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
4. A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients with AIDS Who Have Already Been Treated with Ganciclovir
5. A Study of Stem Cells and Filgrastim
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
|
|
|
|
|
|
|
|
